×
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
NASDAQ:SRRK

Scholar Rock Stock Forecast, Price & News

$5.33
-0.16 (-2.91%)
(As of 07/1/2022 03:59 PM ET)
Add
Compare
Today's Range
$5.13
$5.56
50-Day Range
$4.66
$8.91
52-Week Range
$4.32
$44.95
Volume
66,143 shs
Average Volume
799,933 shs
Market Capitalization
$188.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.67

Scholar Rock MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
512.9% Upside
$32.67 Price Target
Short Interest
Healthy
12.23% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.74
Upright™ Environmental Score
News Sentiment
0.37mentions of Scholar Rock in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$5.87 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.59) to ($2.85) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.32 out of 5 stars

Medical Sector

185th out of 1,427 stocks

Biological Products, Except Diagnostic Industry

26th out of 218 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive SRRK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Scholar Rock and its competitors with MarketBeat's FREE daily newsletter.

Scholar Rock logo

About Scholar Rock (NASDAQ:SRRK) Stock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

SRRK Stock News Headlines

Former Lawyer Went From $50K To $5.3M Trading Options
Slaving away for 70 hrs a week as a lawyer in Chicago, I was miserable. I ran into guys who worked the trading floor at the local exchange. I began trading the same way they did. I started out with $50K (much more than I needed, actually). I grew my $50K into $5.3M
Former Lawyer Went From $50K To $5.3M Trading Options
Slaving away for 70 hrs a week as a lawyer in Chicago, I was miserable. I ran into guys who worked the trading floor at the local exchange. I began trading the same way they did. I started out with $50K (much more than I needed, actually). I grew my $50K into $5.3M
Where Scholar Rock Holding Stands With Analysts
Why Scholar Rock Shares Are Trading Higher Today
What 4 Analyst Ratings Have To Say About Scholar Rock Holding
Scholar Rock announces 25% workforce reduction
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SRRK
Employees
145
Year Founded
N/A

Company Calendar

Last Earnings
11/08/2021
Today
7/04/2022
Next Earnings (Estimated)
8/09/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$32.67
High Stock Price Forecast
$55.00
Low Stock Price Forecast
$19.00
Forecasted Upside/Downside
+512.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.66666666666667
Research Coverage
3 Analysts

Profitability

Net Income
$-131,800,000.00
Net Margins
-236.95%
Pretax Margin
-236.95%

Debt

Sales & Book Value

Annual Sales
$18.82 million
Book Value
$4.90 per share

Miscellaneous

Free Float
34,578,000
Market Cap
$188.16 million
Optionable
Not Optionable
Beta
0.52














Scholar Rock Frequently Asked Questions

Should I buy or sell Scholar Rock stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Scholar Rock in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Scholar Rock stock.
View analyst ratings for Scholar Rock
or view top-rated stocks.

What is Scholar Rock's stock price forecast for 2022?

3 Wall Street analysts have issued 1 year price targets for Scholar Rock's shares. Their SRRK stock forecasts range from $19.00 to $55.00. On average, they expect Scholar Rock's stock price to reach $32.67 in the next year. This suggests a possible upside of 512.9% from the stock's current price.
View analysts' price targets for Scholar Rock
or view top-rated stocks among Wall Street analysts.

How has Scholar Rock's stock price performed in 2022?

Scholar Rock's stock was trading at $24.84 at the beginning of the year. Since then, SRRK stock has decreased by 78.5% and is now trading at $5.33.
View the best growth stocks for 2022 here
.

When is Scholar Rock's next earnings date?

Scholar Rock is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022.
View our earnings forecast for Scholar Rock
.

How were Scholar Rock's earnings last quarter?

Scholar Rock Holding Co. (NASDAQ:SRRK) issued its quarterly earnings results on Monday, November, 8th. The company reported ($1.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by $0.17. The business had revenue of $5.46 million for the quarter, compared to analyst estimates of $4.65 million. Scholar Rock had a negative trailing twelve-month return on equity of 59.99% and a negative net margin of 236.95%. The business's quarterly revenue was up 79.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.79) earnings per share.
View Scholar Rock's earnings history
.

Who are Scholar Rock's key executives?

Scholar Rock's management team includes the following people:
  • Dr. Nagesh K. Mahanthappa MBA, Ph.D., Interim CEO, Pres & Director (Age 57, Pay $356.22k)
  • Mr. Edward H. Myles M.B.A., MBA, CFO, COO & Treasurer (Age 50, Pay $615.87k) (LinkedIn Profile)
  • Dr. Yung H. Chyung M.D., Chief Medical Officer (Age 46, Pay $613.61k)
  • Dr. Gregory John Carven Ph.D., Chief Scientific Officer (Age 46)
  • Ms. Catherine Hu, VP of Investor Relations & Corp. Communications
  • Ms. Junlin Ho J.D., Gen. Counsel & Corp. Sec. (Age 43)
  • Ms. Caryn Parlavecchio, Chief HR Officer (Age 50)
  • Ms. Lisa Amaya Price, Sr. VP of HR
  • Dr. George G. Nomikos M.D., Ph.D., Sr. VP of Medical & Clinical Sciences and Head of Muscle Therapeutic Area
  • Ms. Erin Moore, Sr. VP of Fin. (Age 47)

What other stocks do shareholders of Scholar Rock own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Scholar Rock investors own include Fulcrum Therapeutics (FULC), Coherus BioSciences (CHRS), CTI BioPharma (CTIC), Exelixis (EXEL), GlycoMimetics (GLYC), Nektar Therapeutics (NKTR), SCYNEXIS (SCYX), TG Therapeutics (TGTX), VBI Vaccines (VBIV) and Atara Biotherapeutics (ATRA).

When did Scholar Rock IPO?

(SRRK) raised $76 million in an initial public offering on Thursday, May 24th 2018. The company issued 5,400,000 shares at $13.00-$15.00 per share. Jefferies, Cowen and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Scholar Rock's stock symbol?

Scholar Rock trades on the NASDAQ under the ticker symbol "SRRK."

How do I buy shares of Scholar Rock?

Shares of SRRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Scholar Rock's stock price today?

One share of SRRK stock can currently be purchased for approximately $5.33.

How much money does Scholar Rock make?

Scholar Rock (NASDAQ:SRRK) has a market capitalization of $188.16 million and generates $18.82 million in revenue each year. The company earns $-131,800,000.00 in net income (profit) each year or ($3.04) on an earnings per share basis.

How many employees does Scholar Rock have?

Scholar Rock employs 145 workers across the globe.

How can I contact Scholar Rock?

Scholar Rock's mailing address is 620 MEMORIAL DRIVE 2ND FLOOR, CAMBRIDGE MA, 02139. The official website for Scholar Rock is www.scholarrock.com. The company can be reached via phone at (857) 259-3860, via email at chu@scholarrock.com, or via fax at 866-493-4935.

This page (NASDAQ:SRRK) was last updated on 7/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.